Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Paclitaxel and Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab and Taxane-Based Therapy
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary) ; TVB 2640 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Sep 2017 Status changed from not yet recruiting to recruiting.
- 28 Aug 2017 Planned initiation date changed from 30 Jul 2017 to 30 Sep 2017.